Preparation of a Klebsiella pneumoniae conjugate nanovaccine using glycol-engineered Escherichia coli

• Published in: Microbial cell factories 2023-05, Vol.22 (1), p.95-95, Article 95
• Main Authors: Liu, Yan, Pan, Chao, Wang, Kangfeng, Guo, Yan, Sun, YanGe, Li, Xiang, Sun, Peng, Wu, Jun, Wang, Hengliang, Zhu, Li
• Format: Article
• Language: English
• Subjects: Antibodies; Antigens; Bacterial chassis; Bacterial infections; Bacterial Vaccines; Bioconjugate vaccine; Campylobacter; Chromosomes; Conjugate nanovaccine; Conjugate vaccines; Conjugates; CRISPR; E coli; Escherichia coli; Escherichia coli - metabolism; Gene deletion; Gene expression; Genetically modified organisms; Genomes; Glycan; Glycols - metabolism; Glycoproteins; Glycosyltransferase; Immunization; Infections; Klebsiella; Klebsiella infections; Klebsiella pneumoniae; Klebsiella pneumoniae - genetics; Metabolism; Metabolites; Nanomedicine; Nanotechnology; Pharmaceutical research; Physiological aspects; Plasmids; Polysaccharides; Polysaccharides - metabolism; Prevention; Proteins; Saccharides; Vaccine development; Vaccines; Vaccines, Conjugate
• ISSN: 1475-2859; 1475-2859
• DOI: 10.1186/s12934-023-02099-x

Engineered strains of Escherichia coli have been used to produce bioconjugate vaccines using Protein Glycan Coupling Technology (PGCT). Nanovaccines have also entered the vaccine development arena with advances in nanotechnology and have been significantly developed, but chassis cells for conjugate nanovaccines have not been reported. To facilitate nanovaccine preparation, a generic recombinant protein (SpyCather4573) was used as the acceptor protein for O-linked glycosyltransferase PglL, and a glycol-engineered Escherichia coli strain with these two key components (SC4573 and PglL) integrated in its genome was developed in this study. The targeted glycoproteins with antigenic polysaccharides produced by our bacterial chassis can be spontaneously bound to proteinous nanocarriers with surface exposed SpyTag in vitro to form conjugate nanovaccines. To improve the yields of the targeted glycoprotein, a series of gene cluster deletion experiments was carried out, and the results showed that the deletion of the yfdGHI gene cluster increased the expression of glycoproteins. Using the updated system, to the best of our knowledge, we report for the first time the successful preparation of an effective Klebsiella pneumoniae O1 conjugate nanovaccine (KPO1-VLP), with antibody titers between 4 and 5 (Log10) after triple immunization and up to 100% protection against virulent strain challenge. Our results define a convenient and reliable framework for bacterial glycoprotein vaccine preparation that is flexible and versatile, and the genomic stability of the engineered chassis cells promises a wide range of applications for biosynthetic glycobiology research.